Spondyloarthritis & psoriatic arthritis
Differentiating patients with psoriasis from psoriatic arthritis using collagen biomarkers
Authors' conclusion
This work provides evidence that serum collagen biomarkers are dysregulated in PsC and PsA, as compared to healthy controls. C1M was able to differentiate patients with PsC from PsA and could be a potential biomarker of inflammatory systemic musculoskeletal involvement.
Study context
- Population
- Healthy donors and patients with cutaneous psoriasis (PsC) or psoriatic arthritis (PsA)
- Participants
- 41 / 30 / 30
- Exposure
- Serum collagen biomarkers in PsC vs PsA vs healthy donors
- Healthy donorsn = 41reference
- PsCn = 30
- PsAn = 30
- Outcome
- Serum collagen formation (PRO-C1, PRO-C3, PRO-C4) and degradation (C1M, C2M, C3M, C4M, C10C) biomarkers by ELISA
Main finding
As reported in the abstract
Serum collagen biomarkers
- PsC vs Healthy donors: P < 0.05-p<0.0001
- PsA vs Healthy donors: P < 0.05-p<0.0001
- PsA vs Healthy donors: P < 0.0001
- PsC vs Healthy donors: P = 0.0002
- PsA vs Healthy donors: P = 0.0004
Observational data: associations, not effects.
Further findings
C1M discrimination of PsC vs PsA
- AUROC, C1M separating PsC from PsA
- 0.664
Original publication
Differentiating patients with psoriasis from psoriatic arthritis using collagen biomarkers. Clin Exp Rheumatol. Published 20 January 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →